Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YAZBQ
ADC Name
RM-1995
Synonyms
RM 1995; RM1995
   Click to Show/Hide
Organization
Rakuten Medical, Inc.
Drug Status
Phase 1
Indication
In total 3 Indication(s)
Head and neck squamous carcinoma [ICD11:2C31]
Phase 1
Skin squamous cell carcinoma [ICD11:2C31]
Phase 1
Squamous cell cancer [ICD11:2D60-2D61]
Phase 1
Antibody Name
Undisclosed
Antigen Name
Interferon-stimulated gene 20 kDa protein (ISG20)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05220748
Phase 1
A phase 1 first-in-human, drug-dose escalation study of RM-1995 photoimmunotherapy, as monotherapy or combined with pembrolizumab, in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05220748  Clinical Status Phase 1
Clinical Description A phase 1 first-in-human, drug-dose escalation study of RM-1995 photoimmunotherapy, as monotherapy or combined with pembrolizumab, in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.
References
Ref 1 A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma, NCT05220748

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.